Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab | Neurology Neuroimmunology & Neuroinflammation Background and ObjectivesOcrelizumab labeling advises contraception for women during treatment and for 6–12 months thereafter. Because pregnancies may occur during this time, it is critical to underst...

A paper to be proud of from a fab team. ocrelizumab pregnancy registry data, with over 3000 recorded pregnancies, >800 treated within 3 months of pregnancy and >500 of those with outcomes. We need this kind of data to improve shared decision making around pregnancy.
www.neurology.org/doi/10.1212/...

Oh another new platform, at least this feels nicely familiar...